Cataloging health state utility estimates for Duchenne muscular dystrophy and related conditions by Do, Lauren A, Sedita, Lauren E, Klimchak, Alexa C, Salazar, Rachel, Kim, David D

Get full text

Paving the way for future gene therapies: A case study of scientific spillover from delandistrogene moxeparvovec by Asher, Damon, Dai, Daisy, Klimchak, Alexa C., Sedita, Lauren E., Gooch, Katherine L., Rodino-Klapac, Louise

Get full text

Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States by Klimchak, Alexa C., Patel, Miraj Y., Iorga, Şerban R., Kulkarni, Natasha, Wong, Nathan D.

Get full text

Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States by Klimchak, Alexa C., Sedita, Lauren E., Rodino-Klapac, Louise R., Mendell, Jerry R., McDonald, Craig M., Gooch, Katherine L., Malone, Daniel C.

Get full text

Erratum to ‘Lipid Treatment and Goal Attainment Characteristics among Persons with Atherosclerotic Cardiovascular Disease in the United States’ [American Journal of Preventive Card... by Klimchak, Alexa C., Patel, Miraj Y., Iorga, Şerban R., Kulkarni, Natasha, Wong, Nathan D.

Get full text

Assessment of Phosphorodiamidate Morpholino Oligomer Treatment Patterns for Patients with Duchenne Muscular Dystrophy: A MarketScan Claims Analysis by Klimchak, Alexa C, Signorovitch, James, Innis, Bryan, Laverty, Chamindra G, Gooch, Katherine

Get full text

Quantifying the insurance value for rare diseases: Duchenne muscular dystrophy by Shafrin, Jason, Thahir, Suhail, Klimchak, Alexa C, Audhya, Ivana, Sedita, Lauren E, Romley, John A

Get full text

Discriminatory Properties of the Quality-Adjusted Life Year Based Cost-Effectiveness Analyses for Patients With Disabilities: A Duchenne Muscular Dystrophy Case Study by Klimchak, Alexa C., Sedita, Lauren E., Perfetto, Eleanor M., Gooch, Katherine L., Malone, Daniel C.

Get full text

Observing the Clinical Course of Duchenne Muscular Dystrophy in Medicaid Real-World Healthcare Data by Qian, Christina, Klimchak, Alexa C., Szabo, Shelagh M., Popoff, Evan, Iannaccone, Susan T., Gooch, Katherine L.

Get full text

Assessing the impact of single or short-term administration on a therapy's cost-effectiveness: a hypothetical disease-agnostic model by Klimchak, Alexa C., Sedita, Lauren E., Gooch, Katherine L., Malone, Daniel C.

Get full text

Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Choleste... by Cannon, Christopher P., Sanchez, Robert J., Klimchak, Alexa C., Khan, Irfan, Sasiela, William J., Reynolds, Matthew R., Rosenson, Robert S.

Get full text

Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage by Klimchak, Alexa C, Szabo, Shelagh M, Qian, Christina, Popoff, Evan, Iannaccone, Susan, Gooch, Katherine L

Get full text

Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration–expedited programs by Jenkins, Nola B, Rucker, Julia A, Klimchak, Alexa C, Sedita, Lauren E, Chambers, James D

Get full text

Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease by Cannon, Christopher P., Khan, Irfan, Klimchak, Alexa C., Sanchez, Robert J., Sasiela, William J., Massaro, Joseph M., D'Agostino, Ralph B., Reynolds, Matthew R.

Get full text